Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1H2 | P55055 | 5/20 | 0.57 |
| ▸ | NR1H3 | Q13133 | 4/20 | 0.57 |
| ▸ | ABHD6 | Q9BV23 | 1/20 | 0.51 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.50 |
| ▸ | RIPK1 | Q13546 | 3/20 | 0.46 |
| ▸ | RORC | P51449 | 2/20 | 0.46 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.45 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.44 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.43 |
| ▸ | DTYMK | P23919 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4712983 | 0.93 | NR1H2 (0.58) | NR1H2NR1H3ABHD6ROCK2RIPK1 | |
| SCHEMBL12988184 | 0.89 | NR1H2 (0.57) | NR1H2NR1H3ABHD6ROCK2RORC | |
| SCHEMBL83392 | 0.89 | MEN1 (0.48) | NR1H2NR1H3ABHD6ROCK2P2RX7 | |
| SCHEMBL82172 | 0.89 | NR1H2 (0.57) | NR1H2NR1H3ABHD6ROCK2RORC | |
| SCHEMBL521802 | 0.89 | NR1H2 (0.47) | NR1H2NR1H3ABHD6ROCK2RORC | |
| SCHEMBL38661096 | 0.89 | NR1H2 (0.47) | NR1H2NR1H3ABHD6ROCK2RIPK1 | |
| SCHEMBL522583 | 0.87 | NR1H2 (0.53) | NR1H2NR1H3ABHD6ROCK2GPR119 | |
| SCHEMBL38662977 | 0.87 | GPR119 (0.47) | NR1H2NR1H3ABHD6ROCK2RIPK1 | |
| SCHEMBL12989104 | 0.87 | NR1H2 (0.45) | NR1H2NR1H3ABHD6ROCK2RORC | |
| SCHEMBL12989117 | 0.87 | NR1H2 (0.45) | NR1H2NR1H3ABHD6ROCK2RORC |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100240638-A1 | Organic Compounds and their uses | NOVARTIS AG (CH) | 2010-09-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100240638-A1 | Organic Compounds and their uses | OAT, HAVCR2, CYP3A43 | NR1H2 381/4885NR1H3 275/4885ABHD6 3334/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.